Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma

Michal Fedorko, Michal Stanik, Robert Iliev, Martina Redova-Lojova, Tana Machackova, Marek Svoboda, Dalibor Pacik, Jan Dolezel, Ondrej Slaby, Michal Fedorko, Michal Stanik, Robert Iliev, Martina Redova-Lojova, Tana Machackova, Marek Svoboda, Dalibor Pacik, Jan Dolezel, Ondrej Slaby

Abstract

Serum microRNAs are emerging as a clinically useful tool for early and non-invasive detection of various cancer types including renal cell carcinoma (RCC). Based on our previous results, we performed the study to analyze circulating serum miR-378 and miR-210 in patients with various histological subtypes of RCC. RNA was purified from blood serum samples of 195 RCC patients and 100 healthy controls. The levels of miR-378 and miR-210 in serum were determined absolutely using quantitative real-time PCR. Pre- and postoperative levels of both microRNAs were compared in 20 RCC patients. Significantly increased serum levels of both miR-378 and miR-210 enabled to clearly distinguish RCC patients and healthy controls with 80% sensitivity and 78% specificity if analyzed in combination (p<0.0001), and their levels significantly decreased in the time period of three months after radical nephrectomy (p<0.0001). Increased level of miR-378 positively correlates with disease-free survival (p=0.036) and clinical stage (p=0.0476). The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.

Keywords: biomarker; blood serum; microRNA; renal cell carcinoma.

Figures

Figure 1
Figure 1
MiR-378 and miR-210 as biomarkers in renal cell carcinoma. Differences in serum levels of miR-378 (A) and miR-210 (B) in RCC patients and healthy controls; dynamics of miR-378 (C) and miR-210 (D) levels in blood serum one week and three months after radical nephrectomy; and positive correlation of miR-378 with disease free survival (E) and ROC analysis of miR-378/miR-210 combination for discrimination of renal cell carcinoma patients and healthy controls (F).

References

    1. Yi Z., Fu Y., Zhao S., Zhang X., Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J. Cancer Res. Clin. Oncol. 2010;136:855–862.
    1. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. World Health Organization Classification of Tumours. IARC Press; Lyon, France: 2004. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs; p. 7.
    1. Pichler M., Hutterer G.C., Chromecki T.F., Jesche J., Kampel-Kettner K., Eberhard K., Hoefler G., Pummer K., Zigeuner R. Trends of stage, grade, histology and tumour necrosis in renal cell carcinoma in a European centre surgical series from 1984 to 2010. J. Clin. Pathol. 2012;65:721–724. doi: 10.1136/jclinpath-2012-200797.
    1. Pichler M., Hutterer G.C., Chromecki T.F., Jesche J., Kampel-Kettner K., Pummer K., Zigeuner R. Renal cell carcinoma stage migration in a single European centre over 25 years: Effects on 5- and 10-year metastasis-free survival. Int. Urol. Nephrol. 2012;44:997–1004. doi: 10.1007/s11255-012-0165-5.
    1. Esquela-Kerscher A., Slack F.J. Oncomirs—MicroRNAs with a role in cancer. Nat. Rev. Cancer. 2006;6:259–269. doi: 10.1038/nrc1840.
    1. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008;110:13–21. doi: 10.1016/j.ygyno.2008.04.033.
    1. Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., Svoboda M., Vyzula R., Slaby O. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 2012;10:55. doi: 10.1186/1479-5876-10-55.
    1. Redova M., Poprach A., Besse A., Iliev R., Nekvindova J., Lakomy R., Radova L., Svoboda M., Dolezel J., Vyzula R., et al. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 2013;34:481–491. doi: 10.1007/s13277-012-0573-2.
    1. Iwamoto H., Kanda Y., Sejima T., Osaki M., Okada F., Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int. J. Oncol. 2014;44:53–58.
    1. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., Allen A., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA. 2008;105:10513–10518. doi: 10.1073/pnas.0804549105.
    1. Mahn R., Heukamp L.C., Rogenhofer S., von Ruecker A., Müller S.C., Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77:e9–e16. doi: 10.1016/j.urology.2011.01.020.
    1. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer. 2010;127:118–126. doi: 10.1002/ijc.25007.
    1. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2011;251:499–505. doi: 10.1097/SLA.0b013e3181cc939f.
    1. Hauser S., Wulfken L.M., Holdenrieder S., Moritz R., Ohlmann C.H., Jung V., Becker F., Herrmann E., Walgenbach-Brünagel G., von Ruecker A., et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 2012;36:391–394. doi: 10.1016/j.canep.2012.04.001.
    1. Zhao A., Li G., Péoc’h M., Genin C., Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp. Mol. Pathol. 2013;294:115–120. doi: 10.1016/j.yexmp.2012.10.005.
    1. Zanutto S., Pizzamiglio S., Ghilotti M., Bertan C., Ravagnani F., Perrone F., Leo E., Pilotti S., Verderio P., Gariboldi M., et al. Circulating miR-378 in plasma: A reliable, haemolysis independent biomarker for colorectal cancer. Br. J. Cancer. 2014;110:1001–1007. doi: 10.1038/bjc.2013.819.
    1. Wang K., Yuan Y., Cho J.H., McClarty S., Baxter D., Galas D.J. Comparing the microRNA spectrum between serum and plasma. PLoS ONE. 2012;7:e41561. doi: 10.1371/journal.pone.0041561.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj